SCHEMBL543983

SCHEMBL543983

Cc1c([N+](=O)[O-])ccc(F)c1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.51
TDP1 Q9NUW8 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
CASP6 P55212 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ATM Q13315 1/20 0.42
ALDH1A1 P00352 1/20 0.41
HIF1A Q16665 1/20 0.41
LMNA P02545 3/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
PKM P14618 1/20 0.39
DTYMK P23919 1/20 0.39
CYP3A4 P08684 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1448267 0.86 TDP1 (0.56) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL31146201 0.86 TDP1 (0.56) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL18985184 0.85 TDP1 (0.44) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL21749965 0.84 TDP1 (0.51) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL633629 0.82 TDP1 (0.46) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL1585078 0.82 TDP1 (0.64) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL543121 0.82 TSHR (0.44) TSHRTDP1SMN1; SMN2ALDH1A1HIF1A
SCHEMBL29154301 0.81 TDP1 (0.45) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL7093885 0.81 TSHR (0.62) TSHRTDP1L3MBTL1CASP6SMN1; SMN2
SCHEMBL8364702 0.81 TSHR (0.53) TSHRTDP1L3MBTL1CASP6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
EP-3950676-B1 PREPARATION METHOD FOR AMIDE COMPOUNDS AND APPLICATION THEREOF IN FIELD OF MEDICINE SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) 2026-04-08 EP disclosed
US-12595267-B2 Preparation method for amide compound and application thereof in field of medicine SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) 2026-04-07 US disclosed
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
EP-3950682-B1 PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) 2026-02-11 EP disclosed
EP-4673137-A1 NBD1 MODULATORS AND METHODS OF USING THE SAME Sionna Therapeutics Inc. (US) 2026-01-07 EP disclosed
US-12473298-B2 Amide compounds, preparation method therefor, and use thereof in the medical field SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) 2025-11-18 US disclosed
EP-4583867-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2025-07-16 EP disclosed
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2025-05-29 US disclosed
US-20250154109-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC 2025-05-15 US disclosed
US-20120264734-A1 Aryl- or Heteroaryl-Substituted Benzene Compounds Epizyme, Inc. 2012-10-18 US disclosed
WO-2012082689-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-06-21 WO disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-8110585-B2 Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-07 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
CN-101687810-A Bicyclic compound and pharmaceutical use thereof TAKEDA PHARMACEUTICAL 2010-03-31 CN disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154109-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE SCN8A, TRPV1, SCNN1A TSHR 3667/4885TDP1 4311/4885L3MBTL1 1942/4885
US-12473298-B2 Amide compounds, preparation method therefor, and use thereof in the medical field EZH2, IKZF2, EZH1 TSHR 2569/4885TDP1 4455/4885L3MBTL1 2318/4885
US-12559492-B2 BRAF degraders BRAF, NRAS, HRAS TSHR 75/4885TDP1 1294/4885L3MBTL1 1416/4885
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 TSHR 3819/4885TDP1 2005/4885L3MBTL1 3123/4885
US-12595267-B2 Preparation method for amide compound and application thereof in field of medicine EZH2, BMI1, EHMT1 TSHR 382/4885TDP1 3871/4885L3MBTL1 1175/4885
US-20120264734-A1 Aryl- or Heteroaryl-Substituted Benzene Compounds AHR, ARNT, CYP1B1 TSHR 3819/4885TDP1 2005/4885L3MBTL1 3123/4885
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH TSHR 667/4885TDP1 4627/4885L3MBTL1 3605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.